Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

720

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

August 15, 2028

Study Completion Date

August 15, 2028

Conditions
Alzheimer Dementia
Interventions
DRUG

Huperzine A Controlled-Release Tablets

During the trial, the patients should take huperzine A controlled-release tablets in the morning

DRUG

Donepezil hydrochloride tablets

During the trial, the patients should take donepezil hydrochloride tablets before going to bed in the evening

DRUG

Huperzine A controlled-release tablets placebo; Donepezil hydrochloride tablets placebo

During the trial, the patients should take huperzine A controlled-release tablets placebo in the morning and donepezil hydrochloride tablets placebo before going to bed in the evening

All Listed Sponsors
lead

Wanbangde Pharmaceutical Group Co., LTD

INDUSTRY

NCT07066826 - Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type | Biotech Hunter | Biotech Hunter